Richard S. Kozlowski, Dds in Saint Johnsbury, VT - Dentist

Richard S. Kozlowski, Dds is a dental clinic (Dentist - General Practice) in Saint Johnsbury, Vermont. The current practice location for Richard S. Kozlowski, Dds is 1229 Main St, Saint Johnsbury, Vermont. For appointments, you can reach them via phone at (802) 748-3906. The mailing address for Richard S. Kozlowski, Dds is 1229 Main St, Saint Johnsbury, Vermont and phone number is (802) 748-3906.

Richard S. Kozlowski, Dds is licensed to practice in * (Not Available) (license number ) and its NPI number is 1649896069. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (802) 748-3906.

Contact Information

	Richard S. Kozlowski, Dds
	1229 Main St Saint Johnsbury VT 05819-2697
	(802) 748-3906
	Not Available

Dental Care Clinic Profile

Full Name	Richard S. Kozlowski, Dds
Speciality	Dentist - General Practice
Location	1229 Main St, Saint Johnsbury, Vermont
Authorized Official Name and Position	Julie Charron (OFFICE MANAGER)
Authorized Official Contact	8027483906
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Richard S. Kozlowski, Dds 1229 Main St Saint Johnsbury VT 05819-2697 Ph: (802) 748-3906	Richard S. Kozlowski, Dds 1229 Main St Saint Johnsbury VT 05819-2697 Ph: (802) 748-3906

NPI Details:

NPI Number	1649896069
Provider Enumeration Date	06/22/2020
Last Update Date	06/22/2020

Medical Identifiers

Medical identifiers for Richard S. Kozlowski, Dds such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1649896069	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1223G0001X	Dentist - General Practice	(* (Not Available))	Primary

News Archive

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.

Breathalyzer distinguishes normal and disease-state glucose metabolism

The future of disease diagnosis may lie in a "breathalyzer"-like technology currently under development at the University of Wisconsin-Madison.

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

Richard S. Kozlowski, Dds - Dental Clinic in Saint Johnsbury, VT